<i>Acinetobacter baumannii</i> Resistance to Sulbactam/Durlobactam: A Systematic Review

• Prif Awduron: Luigi Principe (Awdur), Stefano Di Bella (Awdur), Jacopo Conti (Awdur), Mariagrazia Perilli (Awdur), Alessandra Piccirilli (Awdur), Cristina Mussini (Awdur), Giuliana Decorti (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2022-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.
• Notes: 10.3390/antibiotics11121793; 2079-6382
• Keywords: <i>Acinetobacter</i>; sulbactam/durlobactam; sulbactam-durlobactam; resistance; susceptibility; resistances; Therapeutics. Pharmacology; RM1-950
• Source: Antibiotics, Vol 11, Iss 12, p 1793 (2022)

Infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) have limited therapeutic options. Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a systematic review on in vitro studies reporting <i>A. baumannii</i> resistances against sulbactam/durlobactam. We considered "resistant" species to be those with MIC ≥ 8 mg/L. Ten studies were included in the review (9754 tested isolates). Overall, 2.3% of <i>A. baumannii</i> were resistant to sulbactam/durlobactam, and this percentage rose to 3.4% among CRAB subgroups and to 3.7% among colistin-resistant strains. Resistance was 100% among metallo β-lactamase-producing strains. Overall, in 12.5% of cases, sulbactam/durlobactam resistance was associated with the production of NDM-1, in 31.7% of cases with the substitutions in the PBP3 determinants, and in the remaining cases the resistance mechanism was unknown. In conclusion, <i>A. baumannii</i> resistance towards sulbactam/durlobactam is limited, except for MBL-producing strains.